The Russian Direct Investment Fund (RDIF) has proposed that US drugmaker Pfizer start joint trials with Sputnik Light as a booster COVID-19 vaccine shot, the RDIF said on Wednesday.
"Delta cases surge in US & Israel shows mRNA vaccines need a heterogeneous booster to strengthen & prolong immune response. #SputnikV pioneered mix & match approach, combo trials & showed 83.1% efficacy vs Delta. Today RDIF offers Pfizer to start trial with Sputnik Light as booster," it said in a Tweet.
It further said that Sputnik V is the first in the world to offer combo trial to AstraZeneca in November 2020, co-sponsored mix & match trials with AstraZeneca, Moderna and Sinopharm.
"Sputnik V was the 1st in the world to offer combo trial to AstraZeneca in Nov 2020, co-sponsored mix & match trials with AstraZeneca, Moderna & Sinopharm. Since then heterogeneous boosting pioneered by Sputnik proved to be effective vs mutations," it added further.
According to an official statement, the data collected by the health ministry confirms that Sputnik V remains protective against newly detected variants and retains one of the best safety and efficacy parameters.
The Russian Ministry of Health has also published data on Sputnik V's efficacy against the Delta variant. The vaccine is 83.1 per cent effective and shows 6x reduction of infection risk. Sputnik V is also 94.4 per cent effective against hospitalizations with 18x reduction in hospitalisation risk," the RDIF statement said.
Furthermore, real-world data obtained during mass vaccinations in Argentina, Bahrain, Hungary, Mexico, Russia, Serbia, the Philippines and UAE demonstrate lack of serious adverse events (such as CVTs or myocarditis). In several countries where multiple vaccines are used, the Russian vaccine has demonstrate done of the best safety and efficacy parameters.
At present, Sputnik V has been approved in 69 countries with total population exceeding 3.7 billion people - nearly half of the global population.
RDIF has concluded production partnerships with more than 20 companies in 14 countries, including the leading manufacturers in India, China, South Korea, Argentina, Mexico and other countries.
The RDIF statement also said that the two-dose Sputnik V vaccine, the single dose Sputnik Light vaccine is also demonstrating high safety and efficacy results in Argentina. Sputnik Light is the first component of Sputnik V (recombinant human adenovirus serotype number 26 (rAd26)).
In particular, data from the Ministry of Health of the province of Buenos Aires showed that Sputnik Light had helped to elicit antibodies in 94 per cent of those vaccinated and provided for a strong immune response.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU